George Adi Mor
Chief Scientific Officer at Chemomab Therapeutics Ltd. American Depositary Share
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 6 months
- Director since
- 2026
6 months of board service in total across 1 board, counting each seat separately. Longest: Chemomab Therapeutics Ltd. American Depositary Share, 6 months.
Chemomab Therapeutics Ltd. American Depositary Share
Director · Chief Executive Officer
Chief executive roles
Chemomab Therapeutics Ltd. American Depositary Share
· Chief Executive Officer
Since March 2026
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 29, 2026 | Chemomab Therapeutics Ltd. American Depositary Share | Open-market purchase | −4,878 | $2.05 | $10,000 |
| May 29, 2026 | Chemomab Therapeutics Ltd. American Depositary Share | Open-market purchase | −4,926 | $2.08 | $10,246 |
| May 29, 2026 | Chemomab Therapeutics Ltd. American Depositary Share | Other | −31,712 | — | — |
| May 29, 2026 | Chemomab Therapeutics Ltd. American Depositary Share | Other | −18,750 | — | — |
| Jan 3, 2023 | Chemomab Therapeutics Ltd. American Depositary Share | Open-market sale | −7,700 | $5.03 | $38,731 |
| Jan 3, 2023 | Chemomab Therapeutics Ltd. American Depositary Share | Open-market sale | −6,100 | $5.03 | $30,683 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.